












LEO Pharma pipeline overview

2020 Q2

Project*	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
DERMATOLOGY							
Tralokinumab LP0162	An IL-13 anti-inflammatory monoclonal antibody under development for atopic dermatitis.	AstraZeneca 					
Delgocitinib LP0133	A topical pan-JAK inhibitor under development for chronic hand eczema and atopic dermatitis.	JT 					
Anti mIgE⁺B-cell LP0201	A monoclonal antibody under development for atopic dermatitis and allergic asthma.	ONENESS BIO  MICROBIO 					
IL-22R LP0145	An anti-inflammatory monoclonal antibody under development for atopic dermatitis.	argenx 					
Oral H4R antagonist LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for atopic dermatitis.	JW 					
IL-17A PPI LP0200	An IL-17 small-molecule modulator under development for psoriasis.						



*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.

